JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

After a year-long separation, Palestinian twins Mahmoud and Ibraham Al-Attout were reunited on Monday (January 27) in Gaza City. Ibrahim had been forced to move to southern Gaza , while Mahmoud ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing ...

Avior Wealth Management LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.0% during the 4th quarter, according to its most recent 13F filing with the ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart ...